Details of the Drug Therapeutic Target (DTT)
General Information of Drug Therapeutic Target (DTT) (ID: TTP6UO8)
DTT Name | Quinone oxidoreductase (CRYZ) | ||||
---|---|---|---|---|---|
Synonyms | Zeta-crystallin; NADPH:quinone reductase; CRYZ | ||||
Gene Name | CRYZ | ||||
DTT Type |
Literature-reported target
|
[1] | |||
UniProt ID | |||||
TTD ID | |||||
3D Structure | |||||
EC Number |
EC 1.6.5.5
|
||||
Sequence |
MATGQKLMRAVRVFEFGGPEVLKLRSDIAVPIPKDHQVLIKVHACGVNPVETYIRSGTYS
RKPLLPYTPGSDVAGVIEAVGDNASAFKKGDRVFTSSTISGGYAEYALAADHTVYKLPEK LDFKQGAAIGIPYFTAYRALIHSACVKAGESVLVHGASGGVGLAACQIARAYGLKILGTA GTEEGQKIVLQNGAHEVFNHREVNYIDKIKKYVGEKGIDIIIEMLANVNLSKDLSLLSHG GRVIVVGSRGTIEINPRDTMAKESSIIGVTLFSSTKEEFQQYAAALQAGMEIGWLKPVIG SQYPLEKVAEAHENIIHGSGATGKMILLL |
||||
Function |
Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding.
|
||||
The Drug-Metabolizing Enzyme (DME) Role of This DTT
DTT DME Name | NADPH:quinone reductase (CRYZ) | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Name | CRYZ | |||||||||||||||||||||||||||||||||||||||||||||||||||
1 Approved Drug(s) Metabolized by This DTT
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
5 Investigative Drug(s) Metabolized by This DTT
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
References